APA (7th ed.) Citation

Kuo, J. S., Chang, C., Chang, S., Wei, Y., & Chen, C. Rebiopsy Enhances Survival with Afatinib vs. Osimertinib in EGFR Exon 19 Deletion Non-Small Cell Lung Cancer: A Multicenter Study in Taiwan. MDPI AG.

Chicago Style (17th ed.) Citation

Kuo, Jerry Shu-Hung, Cheng-Yu Chang, Shih-Chieh Chang, Yu-Feng Wei, and Chung-Yu Chen. Rebiopsy Enhances Survival with Afatinib Vs. Osimertinib in EGFR Exon 19 Deletion Non-Small Cell Lung Cancer: A Multicenter Study in Taiwan. MDPI AG.

MLA (9th ed.) Citation

Kuo, Jerry Shu-Hung, et al. Rebiopsy Enhances Survival with Afatinib Vs. Osimertinib in EGFR Exon 19 Deletion Non-Small Cell Lung Cancer: A Multicenter Study in Taiwan. MDPI AG.